A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations
Sponsor: Eli Lilly and Company
A PHASE1 clinical study on Advanced Solid Tumor and Metastatic Solid Tumor, this trial is actively recruiting participants. The trial is conducted by Eli Lilly and Company and has accumulated 13 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aurora, United States , Barcelona, Spain , Berlin, Germany , Bordeaux, France , Boston, United States , Chūōku, Japan , Columbus, United States , Denver, United States , Essen, Germany , Fairfax, United States and 19 more locations